Opus Genetics Provides BEST1 Phase 1/2 Trial Timeline for OPGx-BEST1 Data
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
Advertisement
INmune Bio Reports Positive Phase 2 XPro Data
INmune Bio, BOCA RATON, Fla., July 9, 2026 INmune Bio Inc. announced positive new imaging findings from its Phase...
CervoMed Completes Phase 2 Enrollment of Neflamapimod in nfvPPA
CervoMed, BOSTON, July 9, 2026 CervoMed Inc. has announced the successful completion of enrollment in its Phase 2a clinical...
Denali Therapeutics Showcases BBB Innovation at AAIC 2026
SOUTH SAN FRANCISCO, Calif. | July 9, 2026 Denali Therapeutics has announced that co-founder and Chief Executive Officer Ryan...
Sera Prognostics Reports Positive PRIME Trial Results
SALT LAKE CITY | July 9, 2026 Sera Prognostics Inc., a leader in precision pregnancy diagnostics, has announced the...
Freenome Reports Strong SimpleScreen CRC Study Results
BRISBANE, Calif. | July 9, 2026 Freenome, an early cancer detection company advancing blood-based cancer screening technologies, has announced...
Apertura Gene Therapy Advances NPC1 Gene Therapy Research
NEW YORK | July 9, 2026 Apertura Gene Therapy, a biotechnology company developing next-generation adeno-associated virus (AAV) capsids for...
MetaVia Advances DA-1726 Phase 1 Obesity Trial
CAMBRIDGE, Mass. | July 9, 2026 MetaVia Inc., a clinical-stage biotechnology company focused on developing innovative therapies for cardiometabolic...
Octapharma USA Expands FDA Approval for wilate® in Children
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
Viz.ai Expands AI Platform Into Neurodegenerative Disease
SAN FRANCISCO | July 9, 2026 Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, has announced...
Advertisement
